Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
PAPPA encodes a secreted metalloproteinase which cleaves insulin-like growth factor binding proteins (IGFBPs). Additionally we are shipping PAPPA Kits (52) and PAPPA Proteins (21) and many more products for this protein.
Showing 10 out of 210 products:
PAPP-A affects fascicle structure, thereby affecting tendon phenotype.
PAPP-A has a role in development of advanced plaque with necrotic cores and buried fibrous caps (show CAPS Antibodies) in the brachiocephalic artery
these data indicate preferential impact of PAPP-A deficiency on visceral fat in the mouse that is associated with enhanced insulin receptor (show INSR Antibodies) signaling
Studies show a conditional PAPP-A knockout (KO) model for efficacy of tamoxifen-induced floxed PAPP-A excision in various tissues and indicate a significant reduction of neointimal formation after unilateral carotid artery ligation.
absence of PAPP-A is associated with resistance to the development of indicators of diabetic nephropathy in mice
Pregnancy-associated plasma protein (PAPP)-A expressed in the mammary gland controls epithelial cell proliferation and differentiation.
Data conclude that PAPP-A proteolytic activity is required for the lesion-promoting effect of PAPP-A and that its specificity must be directed against IGFBP-4 (show IGFBP4 Antibodies).
observations revealed a novel function of prohibitin (show PHB Antibodies) as a chaperone of p53 (show TP53 Antibodies). Further, they suggest that binding of denatured p53 (show TP53 Antibodies) in intron 1 causes an enhancer effect and increases the transcription of PAPP-A
PAPP-A increases bone formation primarily by increasing IGF bioavailability and other alternative pathways may play a negligible role in mediating the anabolic effect of PAPPA in bone.
PAPPA modulates ovarian function and female fertility by controlling the bioavailability of ovarian insulin (show INS Antibodies)-like growth factors.
PAPP-A in ascites and tissue-associated PAPP-A serve to increase IGF bioactivity and, thereby, to stimulate IGF-IR-mediated ovarian tumor growth.
PAPP-A determination during the first trimester of pregnancy in women at risk for IUGR makes possible the prophylactic treatment and monitoring of pregnancy.
Data indicate that rising pregnancy-associated plasma protein-A (PAPP-A) levels are prognostic in patients with coronary artery disease (CAD (show CAD Antibodies)).
PAPP-A serum concentrations differed significantly between Asian and European women during the first trimester of pregnancy.
The study findings showed that plasma sCD40L, fetuin-A (show AHSG Antibodies), and PAPP-A levels are associated with carotid plaque formation and instability.
For Down syndrome affected pregnancies, the median MoM of first trimester PAPP-A, PlGF (show PGF Antibodies), and AFP (show AFP Antibodies) were significantly reduced, and free-beta-hCG (show CGA Antibodies) were significantly elevated.
Increased PAPP-A in the first trimester is associated with placenta accreta.
Maternal serum PAPP-A was not associated with fetal open spina bifida.
The A>C variation of rs7020782 of PAPPA might be an independent risk factor for carotid plaque development and calcification.
Elevated PAPP-A was associated with fetal macrosomia.
study determined IGFR1 (show IGF1R Antibodies) and PAPP-A expression both in follicles at different stages of development and in ovarian cysts; data indicate that animals with cystic ovarian disease (COD (show SNRPB Antibodies)) have an altered regulation of the IGF system in the ovary and thus allow postulating IGFR1 (show IGF1R Antibodies) expression and PAPP-A secretion as a modulator of IGF1 (show IGF1 Antibodies) in cattle with COD (show SNRPB Antibodies)
in preovulatory follicles, PAPP-A is responsible for IGF-dependent IGFBP-2 (show IGFBP2 Antibodies) degradation
concluded that changes in granulosa cell PAPP-A mRNA levels do not occur during final preovulatory follicular development in cattle
This gene encodes a secreted metalloproteinase which cleaves insulin-like growth factor binding proteins (IGFBPs). It is thought to be involved in local proliferative processes such as wound healing and bone remodeling. Low plasma level of this protein has been suggested as a biochemical marker for pregnancies with aneuploid fetuses.
IGF-dependent IGFBP-4 protease
, insulin-like growth factor-dependent IGF-binding protein 4 protease
, aspecific BCL2 ARE-binding protein 2
, differentially placenta 1 expressed protein
, insulin-like growth factor-dependent IGF binding protein-4 protease
, pregnacy-associated plasma protein A
, PAPPA-like protein
, pregnancy-associated plasma protein A-like protein
, cleaves insulin-like binding protein-4 (IGFBP-4)